We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Learn about Hairy Cell Leukemia-Variant (HCL-V), a rare blood cancer. Understand its causes, symptoms, diagnosis, treatment, and outlook.

Hairy Cell Leukemia-Variant (HCL-V) is an extremely rare and unique type of leukemia, a cancer that affects the blood cells, bone marrow, and related tissues. It was once grouped with a more common form, Hairy Cell Leukemia (HCL), but is now recognized as a distinct condition. HCL-V is significantly rarer than classic HCL, making up only a small fraction of leukemia diagnoses. This blog post aims to provide a clear and practical understanding of HCL-V for Indian readers, covering its causes, symptoms, diagnosis, treatment, and outlook.
Leukemia is a cancer of the blood. It typically affects white blood cells, which are crucial for fighting infections and diseases. In leukemia, these white blood cells don't function correctly, and their numbers can grow uncontrollably, crowding out healthy blood cells. Leukemia can be broadly classified into myeloid and lymphocytic types, depending on the type of white blood cell affected, and acute (fast-growing) or chronic (slow-growing).
Hairy Cell Leukemia (HCL) is named after the distinctive hair-like filaments observed on the surface of affected white blood cells under a microscope. Classic HCL accounts for about 2% of all leukemia cases. HCL-V, on the other hand, is much rarer, estimated to be about one-tenth as common as classic HCL. The key difference lies in their genetic makeup. Classic HCL often involves a mutation in the BRAF V600E gene. However, HCL-V typically has a mutation in the MAP2K1 gene instead. This genetic distinction is crucial because treatments that target the BRAF mutation in classic HCL are not effective for HCL-V.
The exact causes of chronic lymphocytic leukemias (CLLs), including HCL-V, are not fully understood. However, experts believe that genetic changes, known as mutations, play a significant role. These mutations can cause B cells, a type of white blood cell, to multiply excessively and abnormally. While the specific triggers for these mutations in HCL-V are unknown, certain risk factors for CLL in general have been identified:
It's important to remember that these are risk factors, and many people with these factors may never develop the condition, while others without these factors might. HCL-V affects B cells, classifying it as a chronic lymphocytic leukemia (CLL), meaning it typically progresses slowly.
The symptoms of HCL-V are often similar to those of classic HCL. Because HCL-V is a chronic condition, symptoms may develop gradually over time, or some individuals might not experience any noticeable symptoms at all, especially in the early stages. When symptoms do appear, they are often due to the bone marrow's reduced ability to produce healthy blood cells. Common symptoms can include:
It is crucial to note that these symptoms can be caused by many other less serious conditions. Experiencing one or more of these symptoms does not automatically mean you have HCL-V. A proper diagnosis by a healthcare professional is essential.
Diagnosing HCL-V involves a combination of medical history, physical examination, and specific laboratory tests. The process aims to identify the abnormal B cells and confirm the genetic mutations characteristic of HCL-V.
Overall, early action and medically verified advice remain the safest approach.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026

Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026